# High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

> **NCT06662994** · PHASE4 · RECRUITING · sponsor: **Retina Consultants of Orange County** · enrollment: 15 (estimated)

## Conditions studied

- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT06662994
- **Lead sponsor:** Retina Consultants of Orange County
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2026-08-15
- **Final completion:** 2027-08-15
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662994, "High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06662994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*